DNA Ginkgo Bioworks Holdings Inc

  1. Stocks
  2. Healthcare
  3. NYSE: DNA

Price (delayed)

$9.16

Market cap

$598.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.36

Enterprise value

$865.21M

?
Relative Growth: Rel. Growth: 23
Relative Strength: Rel. Strength: 60
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 34

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline ...

Highlights
The EPS rose by 40% year-on-year and by 5% since the previous quarter
The net income has grown by 36% YoY and by 2.7% from the previous quarter
The gross profit has declined by 45% year-on-year and by 16% since the previous quarter
The revenue has declined by 38% year-on-year and by 17% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://ginkgobioworks.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of DNA

DNA stock price

How has the Ginkgo Bioworks Holdings stock price performed over time
Intraday
4.93%
1 week
-3.17%
1 month
-7.57%
1 year
21.16%
YTD
10.23%
QTD
49.43%

Financial performance

How have Ginkgo Bioworks Holdings's revenue and profit performed over time
Revenue
$141.31M
Gross profit
$103.29M
Operating income
-$297.68M
Net income
-$304.39M
Gross margin
73.1%
Net margin
-215.4%
The gross profit has declined by 45% year-on-year and by 16% since the previous quarter
The revenue has declined by 38% year-on-year and by 17% since the previous quarter
The net income has grown by 36% YoY and by 2.7% from the previous quarter
DNA's operating income is up by 36% year-on-year and by 6% since the previous quarter

Price vs fundamentals

How does DNA's price correlate with its fundamentals

Growth

What is Ginkgo Bioworks Holdings's growth rate over time

Valuation

What is Ginkgo Bioworks Holdings stock price valuation
P/E
N/A
P/B
1.28
P/S
3.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.12
The EPS rose by 40% year-on-year and by 5% since the previous quarter
The price to book (P/B) is 58% lower than the 5-year quarterly average of 2.9 but 11% higher than the last 4 quarters average of 1.1
The equity is down by 32% year-on-year and by 13% since the previous quarter
The stock's price to sales (P/S) is 77% less than its 5-year quarterly average of 16.2 but 15% more than its last 4 quarters average of 3.2
The revenue has declined by 38% year-on-year and by 17% since the previous quarter

Efficiency

How efficient is Ginkgo Bioworks Holdings business performance
The company's return on invested capital rose by 42% YoY
The company's return on assets rose by 19% YoY but it fell by 2.7% QoQ
The return on sales has declined by 17% since the previous quarter and by 4% year-on-year
The ROE has grown by 9% YoY but it has contracted by 7% from the previous quarter

Dividends

What is DNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNA.

Financial health

How did Ginkgo Bioworks Holdings financials performed over time
Ginkgo Bioworks Holdings's total assets is 75% higher than its total liabilities
Ginkgo Bioworks Holdings's total assets has decreased by 20% YoY and by 8% QoQ
DNA's total liabilities is down by 9% YoY and by 3.5% from the previous quarter
The debt is 7% smaller than the equity
The debt to equity has grown by 39% YoY and by 13% from the previous quarter
The equity is down by 32% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.